Biologics Drug Development & Manufacturing - Abzena

Why Abzena? Reduced Risk. Unparalleled Expertise. Integrated Biologics & Bioconjugates.

We are the leading fully integrated biologics & bioconjugates CDMO + CRO with a focused approach to get it right from the start. Find out what sets us apart by downloading our brochure or reading on.

Download Brochure

Abzena - Over 1,500 lead candidates discovered and designed

1500+

Lead candidates discovered and designed

Abzena - Over 70 integrated programs delivered in support of INDs

70+

Integrated programs delivered in support of INDs

Abzena - Over 100 production cell lines delivered

200+

Production cell lines delivered

Abzena - 85% of customers request additional work

85%

Customers request additional work

4x programs scaling to PPQ and commercial production.

At Abzena, our focus is on providing a de-risked and streamlined development pathway for a broad range of customers – from emerging biotechs to global pharmaceutical companies. As the leading CDMO + CRO for complex biologics and bioconjugates, we offer fully integrated programs or individual tailored services. Our services and proven technology solutions span early-stage research and discovery through to commercial launch. We ensure that your program progresses smoothly through the critical path and rapidly advances to its next milestone. We are ready to transform your ideas into life-changing medicines for patients in need.

Abzena’s teams share knowledge and insights across disciplines, ensuring seamless transitions between development stages, anticipating challenges before they arise, and helping drive the success of our customers’ programs. Whether supporting integrated hit-to-lead, DNA-to-IND, and late-stage-to-BLA programs or standalone projects, we provide a fully connected US and UK network designed to move medicines to patients faster.

Bringing together discovery, development, mAb production, conjugation, sterile filling, lyophilization, and packaging, this integrated network reduces handoffs, de-risks development, and streamlines progression from early research through commercial readiness. It also helps customers simplify and secure their supply chains and stay ahead of evolving geopolitical and market challenges that could otherwise put critical programs at risk.

Contact Our Experts

Let’s work together to keep moving medicine forward.

Learn more about the leading integrated biologics and bioconjugates CDMO + CRO today.

Contact Our Experts

The focused biopharmaceutical CDMO + CRO

Why Choose Abzena? - About Abzena

Abzena offer a focused approach:

  • Fully integrated end-to-end biologics development partner with services that span early R&D through commercial capabilities
  • High-quality & trusted data that drives development to increase the likelihood of clinical and commercial success
  • Streamlined regulatory support tailored to your program to ensure successful IND or BLA filing
Contact Us

How can Abzena rapidly advance our next-generation biologic?

Integrated Bioconjugate & ADC Development Services - Abzena

Abzena are ready to help accelerate your complex biologics program to its next development stage whilst reducing risk and ensuring scalability. We are focused on finding the right solution, at the right development stage. A solution that delivers on your goals whether that is moving from Hit-to-Lead candidate faster or proven DNA-to-IND to CTA enabling programs and beyond to commercial launch.

Discover Abzena’s end-to-end integrated biologics solutions from discovery to preclinical through to commercialization.

Integrated Biologics Solutions

R&D, Development, Manufacturing Services & Solutions

Abzena has research, development, and cGMP manufacturing facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK, Our services and solutions have been tailored to move your biologic and bioconjugate development programs forward at every stage in the process.

Click below to access our corporate brochure to learn why we are considered to be the leading mAb, bioconjugate, antibody-drug conjugate (ADC), and integrated biologics CDMO + CRO.

Download Brochure

Fully integrated, end-to-end capabilities

 

 

 

 

A trusted partner across all phases of drug discovery and development.

Integrated End-To-end Services - Abzena

Fully integrated support across multiple modalities

cGMP Biologics Manufacturing- Abzena

Abzena offer comprehensive support for:

What sets Abzena apart?

From early discovery through commercial, our experienced scientists work with you side-by-side, functioning seamlessly as part of your team — using real-world insights to bring new ideas to the table and then turning them into action. With quality at the front of everything we do, we plan the best route, steering your drug program toward regulatory approval, and getting it quickly and effectively to patients.

Access our corporate brochure to learn more

Access to Genuine Scientific & Technical Experts

We have over 20 years of experience in delivering solutions at each stage of the development lifecycle from early-stage research and discovery, through lead candidate selection, and onward into process development and GMP manufacture.

Unlike most other service providers, we can provide technical and scientific support that truly spans early-stage research through process development and GMP manufacturing under a single organization to better ensure that the TPP can be achieved. Our global scientific teams have extensive experience in overcoming some of the most challenging and complex biologic and bioconjugate programs, making us the perfect partner for novel and disruptive technologies that other CDMOs may shy away from.

Proactive Problem Solving to Ensure Downstream Success

Our experienced team is focused on getting it right from the start. We identify and address challenges early in drug design to better ensure downstream clinical and commercial success. We also have expertise in fixing and optimizing drugs in later stage development to rescue them from the drug development graveyard.

Diverse & Interconnected Expertise Under a Single Organization

With capabilities ranging from bioassays to cell line development, bioconjugation and clinical and commercial manufacturing, all under one organization, we can reduce the white space in the development path, which ultimately minimizes risk, reduces costs and accelerates timelines for our customers.

As an integrated service provider, we accelerate timelines through the ease of technical and materials transfer, and improved scheduling. Better workflows and processes can also be attained through improved knowledge transfer between internal multidisciplinary experts and the development of a deep understanding of the drug as it progresses from target to lead selection and process development and manufacture.

Bioconjugates (ADCs, AOCs, RDCs) & Chemistry Mammalian Cell Line Development Analytics & Bioassays Clinical Through Commercial Manufacturing

Driven by Innovation to Streamline Development

Our team is always seeking new ways to innovate and streamline development for our customers. Our extensive scientific capabilities and proprietary solutions like EpiScreen® 2.0, Composite Proteins™, Composite Human Antibodies™, AbZelectPRO™, ThioBridge™, and LabZient™ are designed to give your program the best chance of clinical and commercial success.

  • EpiScreen® 2.0 — an extensive suite of bioinformatic and primary human cell-based assays for immunogenicity assessment to inform of potential safety and efficacy risks in the clinic.
  • Composite Human Antibody™ — a platform used for designing safer, more effective, humanized antibodies.
  • Composite Proteins™ — a deimmunization technology that designs safer and more effective therapeutic proteins, devoid of human T cell epitopes, to minimize potential immunogenicity in patients without compromising activity.
  • AbZelectPRO™ — high-yielding cell line development (CLD) platform for accelerating the generation of production cell lines for manufacture of antibodies and recombinant proteins. Now available with two next-generation Glutamine Synthetase (“GS”) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins. These platforms further enhance speed, scalability, and flexibility for our biopharma customers. The new GS knockout platforms are available as a standalone CLD offering or as a fully integrated GMP program.
  • ThioBridge® — a next-generation conjugation linker technology proven to enhance ADC development by overcoming issues with existing technologies to improve stability, potency, and efficacy.
  • LabZient™ — our analytical platform that combines predictive in-silico evaluation with laboratory methods to de-risk the application of platform analytical procedures and expedites the pathway to IND.
Discover Our Solutions
"Abzena has been crucial in advancing and validating our technology and programs. The team is very thoughtful, has strong troubleshooting skills and maintains a high standard in generating quality data with integrity. We highly recommend working with Abzena."

Shiva Bhowmik, PhD

Shiva Bhowmik, PhD | COO
TRIO Pharmaceuticals, Inc.

"We worked with the Abzena team for the design and the initial production of both the mAb and the antibody-chelator conjugate to support our R&D programs. We had a productive and valuable interaction with a highly skilled scientific team and we benefited from the flexibility of the services at this early stage of development."

Tina Bjørnlund Bønsdorff | CSO
Oncoinvent AS

"I’ve never had a CRO project go this smoothly and the ADCs delivered were very high quality. I’m confident that my client will put Abzena at the top of their list for future ADC projects."



David Jackson

David Jackson | Pharmaceutical Consultant & ADC Expert
DYJ Pharma Consulting

“Throughout the development of AGX101, Abzena has worked closely with us to achieve successful GMP manufacturing and quality control. We could not have reached this milestone without Abzena’s expertise, cooperation, and support.”


Paul Jaminet

Paul Jaminet | Co-founder & CEO
Angiex

Our Locations - Abzena

What makes Abzena a unique partner for you?

At Abzena, our unique structure and our values help us build collaborative and long-lasting relationships with our partners. We believe partnering with other organizations allows scientific innovation to flourish. We are a trusted partner across all phases of drug discovery and development, focused on growing together. Our ultimate goal is to get next-generation medicines to patients, faster.

Contact Us

Certifications & Accreditations

Bioconjugate & ADC Development - Abzena

Fully accredited discovery, development and production ready suites on two continents.

  • ISO Class 5, 7, 8 Controlled Environments in US and ISO 9001, 14001 and 45001 in the UK.
  • Compliant with FDA, EMA, and ICH guidelines.
  • Licenses by Califorina FDB and registered with the US FDA since 20005.

Latest News & Insight

Articles

European Pharmaceutical Review: Strategies for scaling complex next-generation biologics

Read More

Articles

Life Sciences Review: Abzena recognized as Top ADC & AOC CDMO Solution Provider of 2026

Read More

Articles

PharmaCircle: Analytical Q&A on methods for Bispecific Antibodies

Read More

Ready to move your medicine forward with Abzena?

Connect With Us